Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05287945 · ClinicalTrials.gov registry record · Phase 1

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

A Phase 1 study of Carcinoma, Renal Cell, sponsored by Oncorena AB.

Recruiting
Registry status
Phase 1
Development phase
75
Enrollment target
3
Study locations

NCT05287945: Recruiting Phase 1 study of Carcinoma, Renal Cell, sponsored by Oncorena AB.

NCT05287945 is a Phase 1 study of Carcinoma, Renal Cell that is actively recruiting participants, run by Oncorena AB. The registered enrollment target is 75 participants, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05287945, a Phase 1 study of Carcinoma, Renal Cell, is actively recruiting participants, sponsored by Oncorena AB.

RECRUITING
Registry status
Phase 1
Development phase
75 participants
Enrollment target
3
Study locations

Study Summary

A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma.

Conditions Studied

Carcinoma, Renal Cell

Interventions

  • DRUG Orellanine

Study Locations (3)

Missouri

  • Washington University in St. Louis - St Louis

Texas

  • University of Texas - MD Anderson Cancer Center - Houston

Other

  • Karolinska University Hospital - Stockholm

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2023-08-04
Est. Completion 2027-12-31
Phase Phase 1
Oncorena AB

1 total trials

What NCT05287945 shows while recruiting

NCT05287945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Orellanine is the first listed.

NCT05287945 reports a single indexed study location in Missouri, Texas, Other.

Frequently Asked Questions

What is clinical trial NCT05287945 about?

NCT05287945 is a clinical study titled "Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma". A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma.

What is the current status of trial NCT05287945?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2023-08-04. Estimated completion is 2027-12-31.

What conditions does trial NCT05287945 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell.

What interventions are being tested in trial NCT05287945?

The interventions under investigation include: Orellanine (DRUG).

Who is sponsoring clinical trial NCT05287945?

This trial is sponsored by Oncorena AB, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05287945 being conducted?

This trial has 3 study locations across Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05287945's enrollment target sits among peer trials

75 18th of 34 higher than 17 of 34 other Carcinoma, Renal Cell trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05287945

Source: ClinicalTrials.gov NCT05287945, the US trial registry maintained by the National Library of Medicine. NCT05287945 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.